Caroline Neumann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Caroline Neumann has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Michael Bauer
Jena University Hospital, Germany
8 shared publicationsHolger Bogatsch
Institute for Medical Informatics, Statistics and Epidemiology (IMISE) and Clinical Trial Centre Leipzig, University of Leipzig, Leipzig, Germany
4 shared publicationsMichael Kiehntopf
Institute for Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Jena, Germany
4 shared publicationsMargit Leitner
Department of Anaesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
3 shared publicationsThomas Lehmann
Center for Clinical Studies, Jena University Hospital, Jena, Germany
3 shared publications- Andrew Retter
Critical Care Department, Guy’s and St Thomas NHS Foundation Trust, London, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Springer Nature in Critical Care
- Vol. 30 (1) , 488
The NLRP3 inflammasome in physiological and dysfunctional host response in human sepsis and critical illness: a narrative review
Background: The NLRP3 inflammasome is a cytosolic multiprotein complex that serves as a key regulator of innate immunity by reacting to pathogen- and damage-associated signals and orchestrating downstream inflammatory responses. Inflammasome activation induces caspase-1-dependent maturation of interleukin (IL)-1β, IL-18 and gasdermin D, which results in pyroptotic cell death. Main text: While tightly controlled inflammasome activation is essential for effective host defence and pathogen clearance, accumulating evidence implicates its dysregulation as a central driver of host response imbalance in critical illness. In conditions such as sepsis and acute respiratory distress syndrome, excessive activation contributes to hyperinflammation, endothelial dysfunction, immunothrombosis, and multi-organ failure. Conversely, insufficient or exhausted inflammasome responses may impair microbial clearance and predispose to secondary infections. These observations underscore the context-dependent and temporally dynamic role of inflammasome signalling as being either protective or pathogenic. Emerging therapeutic strategies aim to restore immune homeostasis through targeted modulation of inflammasome pathways, including IL-1 blockade (e.g., anakinra) and inhibition of upstream signalling components. However, clinical translation remains challenging, requiring improved patient stratification, biomarker-guided approaches, and a deeper understanding of disease heterogeneity. Conclusions: Inflammasome signalling plays a highly dynamic role in critical illness, contributing to effective host defence, if functional, or to pathological inflammation, if dysregulated. Although targeted modulation of inflammasome pathways represents a promising therapeutic strategy, further research is needed to refine patient selection, identify reliable biomarkers, and better characterise disease heterogeneity to enable successful clinical translation.
- 19 September 2026
- Published by Springer Nature in Critical Care
- Vol. 30 (1) , 488
Open AccessThe NLRP3 inflammasome in physiological and dysfunctional host response in human sepsis and critical illness: a narrative review
Background: The NLRP3 inflammasome is a cytosolic multiprotein complex that serves as a key regulator of innate immunity by reacting to pathogen- and damage-associated signals and orchestrating downstream inflammatory responses. Inflammasome activation induces caspase-1-dependent maturation of interleukin (IL)-1β, IL-18 and gasdermin D, which results in pyroptotic cell death. Main text: While tightly controlled inflammasome activation is essential for effective host defence and pathogen clearance, accumulating evidence implicates its dysregulation as a central driver of host response imbalance in critical illness. In conditions such as sepsis and acute respiratory distress syndrome, excessive activation contributes to hyperinflammation, endothelial dysfunction, immunothrombosis, and multi-organ failure. Conversely, insufficient or exhausted inflammasome responses may impair microbial clearance and predispose to secondary infections. These observations underscore the context-dependent and temporally dynamic role of inflammasome signalling as being either protective or pathogenic. Emerging therapeutic strategies aim to restore immune homeostasis through targeted modulation of inflammasome pathways, including IL-1 blockade (e.g., anakinra) and inhibition of upstream signalling components. However, clinical translation remains challenging, requiring improved patient stratification, biomarker-guided approaches, and a deeper understanding of disease heterogeneity. Conclusions: Inflammasome signalling plays a highly dynamic role in critical illness, contributing to effective host defence, if functional, or to pathological inflammation, if dysregulated. Although targeted modulation of inflammasome pathways represents a promising therapeutic strategy, further research is needed to refine patient selection, identify reliable biomarkers, and better characterise disease heterogeneity to enable successful clinical translation.
- Open Access
- 19 August 2026
- Published by Springer Nature in Journal of Intensive Care
- Vol. 14 (1) , 62
Predictive performance of kinetic eGFR, midregional proadrenomedullin, and H3.1 nucleosomes for acute kidney disease in sepsis: a secondary analysis of a large multicentre randomized controlled trial
Background: Sepsis-associated acute kidney injury (SA-AKI) frequently progresses to acute kidney disease (AKD) and is linked to poor outcomes. We evaluated whether combining biomarkers reflecting complementary pathophysiological domains—histone H3.1 nucleosomes (cellular injury), midregional pro-adrenomedullin (MR-proADM; endothelial dysfunction), and kinetic estimated glomerular filtration rate (kinetic eGFR; dynamic renal function)—improves prediction of AKD and renal recovery. Methods: This secondary analysis of the multicentre randomized SISPCT trial included 690 patients with sepsis after exclusion of patients with pre-existing renal replacement therapy or missing AKI data. Biomarkers and kinetic eGFR were assessed at baseline, day 2, and day 7. Multivariable logistic regression models adjusted for age, sex, and non-renal SOFA score were used to assess associations with AKD. Predictive performance was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC). Calibration for the combined models for each day was evaluated using bootstrap-corrected calibration plots. Clinical utility was assessed using decision curve analysis with fivefold cross-validation. Results: AKD occurred in 196 patients (28.4%). At baseline, only MR-proADM was independently associated with AKD (adjusted OR 1.17, 95% CI 1.08–1.28; p < 0.001), whereas H3.1 and kinetic eGFR were not. At day 2 and day 7, only changes in kinetic eGFR were independently associated with AKD (both p < 0.001). Discriminative performance increased over time, with AUCs for the combined model of 0.65 at baseline, 0.70 at day 2, and 0.76 at day 7. At later time points, kinetic eGFR consistently showed the highest discriminative performance based on the point estimates of the AUC. An overall good calibration performance was shown. Decision curve analysis demonstrated only modest and inconsistent additional clinical net benefit of the combined model compared with kinetic eGFR alone. AKD was associated with increased 90-day mortality (55% vs. 24%; risk ratio 2.3, 95% CI 1.9–2.9). Biomarkers showed limited and inconsistent performance for prediction of renal recovery. Conclusions: In patients with sepsis, MR-proADM at baseline and dynamic changes in kinetic eGFR during the first week were independently associated with AKD, whereas histone H3.1 nucleosomes provided limited predictive value. Although multimarker models seemed to modestly improve baseline discrimination, this advantage was not sustained over time and added little clinical benefit beyond kinetic eGFR. These findings highlight the value of dynamic renal function assessment for risk stratification of SA-AKI progression to AKD. Trial registration ClinicalTrials.gov Identifier: NCT00832039.
- 19 August 2026
- Published by Springer Nature in Journal of Intensive Care
- Vol. 14 (1) , 62
Open AccessPredictive performance of kinetic eGFR, midregional proadrenomedullin, and H3.1 nucleosomes for acute kidney disease in sepsis: a secondary analysis of a large multicentre randomized controlled trial
Background: Sepsis-associated acute kidney injury (SA-AKI) frequently progresses to acute kidney disease (AKD) and is linked to poor outcomes. We evaluated whether combining biomarkers reflecting complementary pathophysiological domains—histone H3.1 nucleosomes (cellular injury), midregional pro-adrenomedullin (MR-proADM; endothelial dysfunction), and kinetic estimated glomerular filtration rate (kinetic eGFR; dynamic renal function)—improves prediction of AKD and renal recovery. Methods: This secondary analysis of the multicentre randomized SISPCT trial included 690 patients with sepsis after exclusion of patients with pre-existing renal replacement therapy or missing AKI data. Biomarkers and kinetic eGFR were assessed at baseline, day 2, and day 7. Multivariable logistic regression models adjusted for age, sex, and non-renal SOFA score were used to assess associations with AKD. Predictive performance was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC). Calibration for the combined models for each day was evaluated using bootstrap-corrected calibration plots. Clinical utility was assessed using decision curve analysis with fivefold cross-validation. Results: AKD occurred in 196 patients (28.4%). At baseline, only MR-proADM was independently associated with AKD (adjusted OR 1.17, 95% CI 1.08–1.28; p < 0.001), whereas H3.1 and kinetic eGFR were not. At day 2 and day 7, only changes in kinetic eGFR were independently associated with AKD (both p < 0.001). Discriminative performance increased over time, with AUCs for the combined model of 0.65 at baseline, 0.70 at day 2, and 0.76 at day 7. At later time points, kinetic eGFR consistently showed the highest discriminative performance based on the point estimates of the AUC. An overall good calibration performance was shown. Decision curve analysis demonstrated only modest and inconsistent additional clinical net benefit of the combined model compared with kinetic eGFR alone. AKD was associated with increased 90-day mortality (55% vs. 24%; risk ratio 2.3, 95% CI 1.9–2.9). Biomarkers showed limited and inconsistent performance for prediction of renal recovery. Conclusions: In patients with sepsis, MR-proADM at baseline and dynamic changes in kinetic eGFR during the first week were independently associated with AKD, whereas histone H3.1 nucleosomes provided limited predictive value. Although multimarker models seemed to modestly improve baseline discrimination, this advantage was not sustained over time and added little clinical benefit beyond kinetic eGFR. These findings highlight the value of dynamic renal function assessment for risk stratification of SA-AKI progression to AKD. Trial registration ClinicalTrials.gov Identifier: NCT00832039.
- Open Access
- 14 August 2026
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
The Uncovered Role of Interferons in Sepsis: From Pathogenesis to Precision Immunotherapy
Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection resulting in organ dysfunction. While traditional paradigms have emphasized proinflammatory cytokines, such as tumor necrosis factor-α and interleukin-1β, interferons (IFNs) are increasingly recognized as critical yet underexplored mediators of sepsis pathobiology. IFNs are central regulators of innate and adaptive immunity and have emerged as key mediators of the immune alterations observed during sepsis. Type I IFNs (IFN-α/β), type II IFN (IFN-γ), and type III IFNs exert pleiotropic effects on immune activation, pathogen clearance, endothelial function, immunometabolism, and tissue injury. While early IFN responses support antimicrobial defense, sustained or dysregulated signaling contributes to hyperinflammation, endothelial dysfunction, immune exhaustion, coagulopathy, and multiorgan failure. Increasing evidence from experimental models and clinical studies suggests that IFN activity differs substantially among septic patients and may define biologically distinct immune endotypes. IFN-stimulated gene signatures and IFN-related biomarkers therefore represent promising tools for patient stratification and precision immunotherapy. This review summarizes the biology of IFNs relevant to sepsis, their role across different disease phases, their contribution to organ dysfunction, and emerging therapeutic strategies targeting IFN pathways. Current evidence supports a shift toward biomarker-guided and phase-specific immunomodulation aimed at restoring immune homeostasis while minimizing harmful inflammation.
- 14 August 2026
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
Open AccessThe Uncovered Role of Interferons in Sepsis: From Pathogenesis to Precision Immunotherapy
Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection resulting in organ dysfunction. While traditional paradigms have emphasized proinflammatory cytokines, such as tumor necrosis factor-α and interleukin-1β, interferons (IFNs) are increasingly recognized as critical yet underexplored mediators of sepsis pathobiology. IFNs are central regulators of innate and adaptive immunity and have emerged as key mediators of the immune alterations observed during sepsis. Type I IFNs (IFN-α/β), type II IFN (IFN-γ), and type III IFNs exert pleiotropic effects on immune activation, pathogen clearance, endothelial function, immunometabolism, and tissue injury. While early IFN responses support antimicrobial defense, sustained or dysregulated signaling contributes to hyperinflammation, endothelial dysfunction, immune exhaustion, coagulopathy, and multiorgan failure. Increasing evidence from experimental models and clinical studies suggests that IFN activity differs substantially among septic patients and may define biologically distinct immune endotypes. IFN-stimulated gene signatures and IFN-related biomarkers therefore represent promising tools for patient stratification and precision immunotherapy. This review summarizes the biology of IFNs relevant to sepsis, their role across different disease phases, their contribution to organ dysfunction, and emerging therapeutic strategies targeting IFN pathways. Current evidence supports a shift toward biomarker-guided and phase-specific immunomodulation aimed at restoring immune homeostasis while minimizing harmful inflammation.
- Open Access
- 3 August 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (10) , 2567-2578
H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Secondary Analysis of the SISPCT Randomized Control Trial
OBJECTIVES: The release of neutrophil extracellular traps is a key immune host defense mechanism that can contribute to organ damage during sepsis if excessive. We evaluated presentation H3.1 nucleosome levels in patients with sepsis, septic shock, and sepsis-associated acute kidney injury (AKI). We sought to determine if plasma H3.1 nucleosome levels could serve as predictive biomarkers for both renal replacement therapy (RRT) requirements and 28-day mortality. DESIGN: A secondary analysis of prospectively collected samples from the large multicenter Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients with Severe Sepsis or Septic Shock (SISPCT) trial. SETTING: Patients from 33 ICUs in Germany recruited between November 6, 2009, and June 6, 2013, including a 90-day follow-up period. Patients: A total of 971 patients with complete data on plasma H3.1 admission levels with sepsis and septic shock, and 927 patients with complete data on RRT requirements. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We evaluated associations between H3.1 levels and mortality and the time to commencement of RRT using multivariable Cox regression. A total of 443 patients (45.6%) presented with sepsis, and 520 patients (53.6%) had septic shock. Admission H3.1 levels were higher in patients with septic shock than sepsis (median, 921.84 vs. 432.71 ng/mL; p < 0.001). In a multivariable analysis for 28-day mortality, a one unit increase in log10 H3.1 levels was associated with a 48% increase in 28-day mortality (adjusted hazard ratio [HR], 1.48, 95% CI, 1.07–2.04; p = 0.02). Plasma H3.1 was also higher in patients with stage 3 AKI requiring RRT with septic shock vs. sepsis (1832 vs. 801.4 ng/mL; p = 0.01). In a multivariable Cox regression controlling for maximum lactate, procalcitonin, and C-reactive protein levels, plasma H3.1 levels were significantly higher in patients who developed AKI requiring RRT when compared with patients who did not develop AKI, with one log10 increase of H3.1 increasing the risk of 28-day RRT by 80% (adjusted HR, 1.8; 95% CI, 1.34–2.40; p < 0.001). CONCLUSIONS: Elevated levels of H3.1 nucleosomes at admission are associated with mortality and AKI requiring RRT. Trial Registration: The trial was registered in clinicaltrials.gov, identifier: NCT00832039.
- 3 August 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (10) , 2567-2578
Open AccessH3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Secondary Analysis of the SISPCT Randomized Control Trial
OBJECTIVES: The release of neutrophil extracellular traps is a key immune host defense mechanism that can contribute to organ damage during sepsis if excessive. We evaluated presentation H3.1 nucleosome levels in patients with sepsis, septic shock, and sepsis-associated acute kidney injury (AKI). We sought to determine if plasma H3.1 nucleosome levels could serve as predictive biomarkers for both renal replacement therapy (RRT) requirements and 28-day mortality. DESIGN: A secondary analysis of prospectively collected samples from the large multicenter Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients with Severe Sepsis or Septic Shock (SISPCT) trial. SETTING: Patients from 33 ICUs in Germany recruited between November 6, 2009, and June 6, 2013, including a 90-day follow-up period. Patients: A total of 971 patients with complete data on plasma H3.1 admission levels with sepsis and septic shock, and 927 patients with complete data on RRT requirements. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We evaluated associations between H3.1 levels and mortality and the time to commencement of RRT using multivariable Cox regression. A total of 443 patients (45.6%) presented with sepsis, and 520 patients (53.6%) had septic shock. Admission H3.1 levels were higher in patients with septic shock than sepsis (median, 921.84 vs. 432.71 ng/mL; p < 0.001). In a multivariable analysis for 28-day mortality, a one unit increase in log10 H3.1 levels was associated with a 48% increase in 28-day mortality (adjusted hazard ratio [HR], 1.48, 95% CI, 1.07–2.04; p = 0.02). Plasma H3.1 was also higher in patients with stage 3 AKI requiring RRT with septic shock vs. sepsis (1832 vs. 801.4 ng/mL; p = 0.01). In a multivariable Cox regression controlling for maximum lactate, procalcitonin, and C-reactive protein levels, plasma H3.1 levels were significantly higher in patients who developed AKI requiring RRT when compared with patients who did not develop AKI, with one log10 increase of H3.1 increasing the risk of 28-day RRT by 80% (adjusted HR, 1.8; 95% CI, 1.34–2.40; p < 0.001). CONCLUSIONS: Elevated levels of H3.1 nucleosomes at admission are associated with mortality and AKI requiring RRT. Trial Registration: The trial was registered in clinicaltrials.gov, identifier: NCT00832039.
- Open Access
- 18 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0339763
NephroPOC - Risk assessment and prediction of acute kidney injury in emergency patients with suspected organ dysfunction: Secondary analysis from the prospective observational LifePOC study
We aimed to assess markers and risk factors for imminent acute kidney injury (AKI) in emergency patients, as risk stratification in the emergency department is currently not widely used. Using data from a sub-cohort (440 patients) of the prospective multicentre LifePOC study (1434 patients), proenkephalin A 119−159 (penKid) was assessed for early identification of subclinical kidney damage compared to serum creatinine in emergency patients with a qSOFA score ≥1. Logistic regression was applied to assess the usefulness of penKid, four further biomarkers (midregional pro-adrenomedullin, bioactive adrenomedullin, dipeptidyl-peptidase-3, procalcitonin) and clinical risk factors to predict AKI within 24 h, 48 h and 72 h after admission, need for organ support and 28-day mortality. PenKid and bio-adrenomedullin performed moderately to predict AKI within 48 h (AUC 0.645, 95% CI: 0.582–0.703 and AUC 0.647, 95% CI: 0.583–0.707, respectively). Pre-existing chronic kidney disease (OR 2.36, 95% CI: 1.06–5.27), confirmed sepsis (OR 2.41, 95% CI: 1.28–4.56), mechanical ventilation (OR 3.03, 95% CI: 1.48–6.19), and elevated levels of penKid (OR 2.21, 95% CI: 1.60–3.07) at admission were associated with an increased risk of AKI whereas a restrictive fluid management (OR 0.43, 95% CI: 0.26–0.71) was associated with a lower risk of AKI. Patients at high AKI risk may be identified based on specific risk factors, bio-ADM and penKid. The trial was registered in the German Registry for Clinical Trials (DRKS00011188) on 20 October 2016.
- 18 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0339763
Open AccessNephroPOC - Risk assessment and prediction of acute kidney injury in emergency patients with suspected organ dysfunction: Secondary analysis from the prospective observational LifePOC study
We aimed to assess markers and risk factors for imminent acute kidney injury (AKI) in emergency patients, as risk stratification in the emergency department is currently not widely used. Using data from a sub-cohort (440 patients) of the prospective multicentre LifePOC study (1434 patients), proenkephalin A 119−159 (penKid) was assessed for early identification of subclinical kidney damage compared to serum creatinine in emergency patients with a qSOFA score ≥1. Logistic regression was applied to assess the usefulness of penKid, four further biomarkers (midregional pro-adrenomedullin, bioactive adrenomedullin, dipeptidyl-peptidase-3, procalcitonin) and clinical risk factors to predict AKI within 24 h, 48 h and 72 h after admission, need for organ support and 28-day mortality. PenKid and bio-adrenomedullin performed moderately to predict AKI within 48 h (AUC 0.645, 95% CI: 0.582–0.703 and AUC 0.647, 95% CI: 0.583–0.707, respectively). Pre-existing chronic kidney disease (OR 2.36, 95% CI: 1.06–5.27), confirmed sepsis (OR 2.41, 95% CI: 1.28–4.56), mechanical ventilation (OR 3.03, 95% CI: 1.48–6.19), and elevated levels of penKid (OR 2.21, 95% CI: 1.60–3.07) at admission were associated with an increased risk of AKI whereas a restrictive fluid management (OR 0.43, 95% CI: 0.26–0.71) was associated with a lower risk of AKI. Patients at high AKI risk may be identified based on specific risk factors, bio-ADM and penKid. The trial was registered in the German Registry for Clinical Trials (DRKS00011188) on 20 October 2016.
- 14 January 2026
- Published by Springer Nature in Die Anaesthesiologie
- Vol. 75 (3) , 203-204
Effective treatment of sepsis demands guidelines implementation tailored to available resources
- 14 January 2026
- Published by Springer Nature in Die Anaesthesiologie
- Vol. 75 (3) , 203-204
Effective treatment of sepsis demands guidelines implementation tailored to available resources
- Open Access
- 8 December 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (12) , e1358
Fatal Triad of Subarachnoid Hemorrhage, Cervical Hematoma, and Upper Airway Obstruction in a Patient With Neurofibromatosis Type 1: A Case Report
BACKGROUND: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder, characterized by neurocutaneous lesions. NF1 has a high degree of clinical variability, which can include multiple neoplasia as well as cutaneous, vascular, osseous, and cognitive features. When vascular involvement occurs, NF1 can lead to aneurysms or arteriovenous malformations, which may rupture and cause life-threatening complications. CASE SUMMARY: We present a case of primary subarachnoid hemorrhage, complicated by spontaneous and rapidly progressing hemorrhage from the left subclavian artery resulting in upper airway obstruction and hypoxia in a patient with NF1. Treatment of this patient included surgical airway management, emergency hematoma evacuation, and vascular reconstructive surgery. Close collaboration between radiology, vascular surgery, and anesthesiology was essential to prevent patient’s death. CONCLUSIONS: Awareness of rare diseases such as NF1 is essential in critical care settings. Patients presenting with café-au-lait spots or cutaneous neurofibromas are at risk of vascular complications due to vascular fragility. This case of dual bleeding sources and airway obstruction from a neck hematoma underscores the need for interdisciplinary management. The role of proactive vascular screening in critically ill NF1 patients remains uncertain. Future approaches may incorporate advanced imaging and biomarker development to better stratify vascular risk and guide individualized care.
- 8 December 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (12) , e1358
Open AccessFatal Triad of Subarachnoid Hemorrhage, Cervical Hematoma, and Upper Airway Obstruction in a Patient With Neurofibromatosis Type 1: A Case Report
BACKGROUND: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder, characterized by neurocutaneous lesions. NF1 has a high degree of clinical variability, which can include multiple neoplasia as well as cutaneous, vascular, osseous, and cognitive features. When vascular involvement occurs, NF1 can lead to aneurysms or arteriovenous malformations, which may rupture and cause life-threatening complications. CASE SUMMARY: We present a case of primary subarachnoid hemorrhage, complicated by spontaneous and rapidly progressing hemorrhage from the left subclavian artery resulting in upper airway obstruction and hypoxia in a patient with NF1. Treatment of this patient included surgical airway management, emergency hematoma evacuation, and vascular reconstructive surgery. Close collaboration between radiology, vascular surgery, and anesthesiology was essential to prevent patient’s death. CONCLUSIONS: Awareness of rare diseases such as NF1 is essential in critical care settings. Patients presenting with café-au-lait spots or cutaneous neurofibromas are at risk of vascular complications due to vascular fragility. This case of dual bleeding sources and airway obstruction from a neck hematoma underscores the need for interdisciplinary management. The role of proactive vascular screening in critically ill NF1 patients remains uncertain. Future approaches may incorporate advanced imaging and biomarker development to better stratify vascular risk and guide individualized care.
- Open Access
- 3 December 2025
- Published by Springer Nature in Die Anaesthesiologie
- Vol. 75 (1) , 80
Erratum zu: Update 2025 der S3-Leitlinie: „Sepsis – Prävention, Diagnose, Therapie und Nachsorge“
- 3 December 2025
- Published by Springer Nature in Die Anaesthesiologie
- Vol. 75 (1) , 80
Open AccessErratum zu: Update 2025 der S3-Leitlinie: „Sepsis – Prävention, Diagnose, Therapie und Nachsorge“
- Open Access
- 30 October 2025
- Published by Springer Nature in Die Anaesthesiologie
- Vol. 74 (12) , 827-838
Update 2025 der S3-Leitlinie: „Sepsis – Prävention, Diagnose, Therapie und Nachsorge“
Zusammenfassung Am 25.07.2025 wurde das Update der S3-Leitlinie „Sepsis – Prävention, Diagnose, Therapie und Nachsorge“ veröffentlicht. Die neue Leitlinie adressiert 29 neue und 16 geänderte Empfehlungen, wobei 43 Empfehlungen zur Vorversion unverändert blieben. Das 2025-Update ist eine gezielte Anpassung an die international anerkannten Empfehlungen der Surviving Sepsis Campaign von 2021. Schwerpunkte sind eine frühzeitige, individualisierte und evidenzbasierte Therapie, die Integration strukturierter Nachsorge nach der Krankenhausentlassung und eine stärkere Ausrichtung auf patientenzentrierte Gesamtbetreuung über die akute Behandlung hinaus. Trotz Fortschritten in der Früherkennung, Antibiotikatherapie und intensivmedizinischer Betreuung von Patienten bleiben die Sepsis und der septische Schock potenziell lebensbedrohliche Erkrankungen, was die Notwendigkeit einer frühzeitigen Diagnosestellung und der Einleitung einer bedarfsgerechten Therapie unterstreicht.
- 30 October 2025
- Published by Springer Nature in Die Anaesthesiologie
- Vol. 74 (12) , 827-838
Open AccessUpdate 2025 der S3-Leitlinie: „Sepsis – Prävention, Diagnose, Therapie und Nachsorge“
Zusammenfassung Am 25.07.2025 wurde das Update der S3-Leitlinie „Sepsis – Prävention, Diagnose, Therapie und Nachsorge“ veröffentlicht. Die neue Leitlinie adressiert 29 neue und 16 geänderte Empfehlungen, wobei 43 Empfehlungen zur Vorversion unverändert blieben. Das 2025-Update ist eine gezielte Anpassung an die international anerkannten Empfehlungen der Surviving Sepsis Campaign von 2021. Schwerpunkte sind eine frühzeitige, individualisierte und evidenzbasierte Therapie, die Integration strukturierter Nachsorge nach der Krankenhausentlassung und eine stärkere Ausrichtung auf patientenzentrierte Gesamtbetreuung über die akute Behandlung hinaus. Trotz Fortschritten in der Früherkennung, Antibiotikatherapie und intensivmedizinischer Betreuung von Patienten bleiben die Sepsis und der septische Schock potenziell lebensbedrohliche Erkrankungen, was die Notwendigkeit einer frühzeitigen Diagnosestellung und der Einleitung einer bedarfsgerechten Therapie unterstreicht.
- Open Access
- 30 May 2025
- Published by Springer Nature in Infection
- Vol. 53 (6) , 2383-2395
Clinical value of circulating bioactive adrenomedullin for prediction of outcome and hydrocortisone response in sepsis patients—a post-hoc analysis of the HYPRESS trial
Purpose: Sepsis requires stratification for host-directed therapies through the discovery of adequate biomarkers enabling prediction of outcomes and treatment responses. Adrenomedullin has previously demonstrated potential for prognostic enrichment. This study aimed to assess associations of bioactive adrenomedullin (bio-ADM) levels at ICU admission and sepsis outcomes and to evaluate the potential of bio-ADM as marker to identify subgroups of patients with moderate disease severity that might benefit from hydrocortisone treatment. Methods: We used data from the HYPRESS trial (NCT00670254) to investigate, if bio-ADM is useful to predict sepsis outcomes (septic shock, 90- and 180-day mortality) and benefit or harm by hydrocortisone treatment. Optimal cut-offs for outcome predictions were determined by Youden’s index. Logistic regression was used to assess bio-ADM subgroups and treatment interaction. Results: Bio-ADM levels differed significantly in patients with or without septic shock within 14 days (p = 0.011). While the area under the ROC curve (AUC) was only 0.603 (CI 0.531–0.676), patient subgrouping using bio-ADM levels showed significantly higher cumulative incidence of septic shock within 14 days in the subgroup of patients with bio-ADM levels ≥ 37 pg/mL (p < 0.001). The odds ratio for the development of septic shock in this group was 4.67 (95% CI 1.53, 20.3, p = 0.016). A bio-ADM cut-off of ≥ 136 pg/mL was predictive for 90-day (OR 8.21, 95% CI 2.46–27.9, p < 0.001) and 180-day mortality (OR 4.87, 95% CI 1.49–16.0, p = 0.008). Hydrocortisone therapy did not reduce the incidence of septic shock (OR 1.59, 95% CI 0.37–8.15, p = 0.54), 90-day (OR 1.53, p = 0.23) or 180-day mortality (OR 1.41, p = 0.25), regardless of bio-ADM stratification (interaction term p = 0.58 for septic shock; p = 0.31 for 90-day mortality; p = 0.51 for 180-day mortality). Conclusions: Whereas bio-ADM levels are associated with sepsis outcomes, our data do not indicate usefulness of the marker to identify patients potentially benefitting from hydrocortisone therapy.
- 30 May 2025
- Published by Springer Nature in Infection
- Vol. 53 (6) , 2383-2395
Open AccessClinical value of circulating bioactive adrenomedullin for prediction of outcome and hydrocortisone response in sepsis patients—a post-hoc analysis of the HYPRESS trial
Purpose: Sepsis requires stratification for host-directed therapies through the discovery of adequate biomarkers enabling prediction of outcomes and treatment responses. Adrenomedullin has previously demonstrated potential for prognostic enrichment. This study aimed to assess associations of bioactive adrenomedullin (bio-ADM) levels at ICU admission and sepsis outcomes and to evaluate the potential of bio-ADM as marker to identify subgroups of patients with moderate disease severity that might benefit from hydrocortisone treatment. Methods: We used data from the HYPRESS trial (NCT00670254) to investigate, if bio-ADM is useful to predict sepsis outcomes (septic shock, 90- and 180-day mortality) and benefit or harm by hydrocortisone treatment. Optimal cut-offs for outcome predictions were determined by Youden’s index. Logistic regression was used to assess bio-ADM subgroups and treatment interaction. Results: Bio-ADM levels differed significantly in patients with or without septic shock within 14 days (p = 0.011). While the area under the ROC curve (AUC) was only 0.603 (CI 0.531–0.676), patient subgrouping using bio-ADM levels showed significantly higher cumulative incidence of septic shock within 14 days in the subgroup of patients with bio-ADM levels ≥ 37 pg/mL (p < 0.001). The odds ratio for the development of septic shock in this group was 4.67 (95% CI 1.53, 20.3, p = 0.016). A bio-ADM cut-off of ≥ 136 pg/mL was predictive for 90-day (OR 8.21, 95% CI 2.46–27.9, p < 0.001) and 180-day mortality (OR 4.87, 95% CI 1.49–16.0, p = 0.008). Hydrocortisone therapy did not reduce the incidence of septic shock (OR 1.59, 95% CI 0.37–8.15, p = 0.54), 90-day (OR 1.53, p = 0.23) or 180-day mortality (OR 1.41, p = 0.25), regardless of bio-ADM stratification (interaction term p = 0.58 for septic shock; p = 0.31 for 90-day mortality; p = 0.51 for 180-day mortality). Conclusions: Whereas bio-ADM levels are associated with sepsis outcomes, our data do not indicate usefulness of the marker to identify patients potentially benefitting from hydrocortisone therapy.